Table 2 Multivariable Cox model for overall survival in patients whose baseline and disease characteristics are known (n = 443).

From: A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma

 

OS univariate HR (95% CI)

p–value

OS multivariate HR (95% CI)

p–value

Age

1.04 (1.03–1.05)

 < 0.001

1.06 (1.04–1.07)

 < 0.001

Age over 60 years at diagnosis

2.49 (2.08–3.00)

 < 0.001

1.61 (1.08–2.40)

0,019

Male gender

1.10 (0.95–1.28)

0.21

1.27 (1.01–1.60)

0.041

B-symptoms

1.41 (1.13–1.75)

0.002

1.19 (0.94–1.51)

0.156

Ann Arbor III-IV

2.00 (1.54–2.61)

 < 0.001

1.85 (1.34–2.56)

 < 0.001

Extranodal involvement

1.77 (1.38–2.25)

 < 0.001

1.13 (0.27–1.57)

0.434

BM

1.39 (1.09–1.78)

0.01

1.26 (0.93–1.72)

0.137

Spleen

1.01 (0.78–1.31)

0.94

not included

 

GI

2.24 (1.72–2.92)

 < 0.001

1.52 (0.85–2.70)

0.16

Skin

1.07 (0.81–1.42)

0.64

not included

 

Lung

1.43 (1.02–2.00)

0.05

1.43 (0.97–2.11)

0.074

CNS

2.67 (1.26–5.65)

0.027

not included

 

Liver

1.13 (0.75–1.71)

0.57

not included

 

Bone

0.54 (0.31–0.94)

0.016

0.68 (0.38–1.21)

0.19

Kidney

2.94 (1.21–7.13)

0.042

2.77 (1.01–7.56)

0.05

PTCL NOS

1.00 reference

 

1.00 reference

 

ALCL ALK-

0.63 (0.48–0.82)

 < 0.001

0.88 (0.62–1.25)

0.48

ALCL ALK + 

0.11 (0.06–0.21)

 < 0.001

0.31 (0.12–0.77)

0.011

ALCL ALK unknown

0.97 (0.67–1.39)

0.862

1.54 (0.73–3.22)

0.26

AITL

0.86 (0.71–1.03)

0.09

0.62 (0.47–0.82)

0.001

EATL

1.31 (1.03–1.68)

0.033

1.59 (0.85–2.98)

0.151

ENKTCL

0.78 (0.48–1.26)

0.29

1.91 (1.03–3.56)

0.041

HSCTL

1.87 (0.77–4.52)

0.21

4.09 (1.46–11.47)

0.007

  1. BM, bone marrow; CNS, central nervous system; GI, gastrointestinal tract; OS, overall survival; CI, confidence interval; HR, hazard ratio.